Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease

Abstract Paclitaxel-coated balloon (PCB) treatment has shown promise for intracranial atherosclerotic disease (ICAD). However, studies on restenosis and its associated factors after PCB use are lacking. This study aimed to elucidate risk factors of restenosis after PCB treatment for ICAD. We retrosp...

Full description

Saved in:
Bibliographic Details
Main Authors: Yingkun Chen, Kaiyue Dong, Yun Song, Lili Sun, Meimei Zheng, Hao Yin, Jun Zhang, Wei Wang, Yao Meng, Weili Li, Xiao He, Wei Zhao, Ju Han
Format: Article
Language:English
Published: Nature Portfolio 2025-05-01
Series:Scientific Reports
Subjects:
Online Access:https://doi.org/10.1038/s41598-025-02538-2
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849325924099555328
author Yingkun Chen
Kaiyue Dong
Yun Song
Lili Sun
Meimei Zheng
Hao Yin
Jun Zhang
Wei Wang
Yao Meng
Weili Li
Xiao He
Wei Zhao
Ju Han
author_facet Yingkun Chen
Kaiyue Dong
Yun Song
Lili Sun
Meimei Zheng
Hao Yin
Jun Zhang
Wei Wang
Yao Meng
Weili Li
Xiao He
Wei Zhao
Ju Han
author_sort Yingkun Chen
collection DOAJ
description Abstract Paclitaxel-coated balloon (PCB) treatment has shown promise for intracranial atherosclerotic disease (ICAD). However, studies on restenosis and its associated factors after PCB use are lacking. This study aimed to elucidate risk factors of restenosis after PCB treatment for ICAD. We retrospectively enrolled consecutive patients who had been successfully treated with PCBs for symptomatic ICAD between January 2016 and December 2022. Eligible patients were classified into “no-restenosis” and “restenosis” groups by follow-up DSA. Demographic, clinical, laboratory test, and angiographic data were analyzed. Multivariate logistic regression analysis was used to explore the risk factors of restenosis after PCB treatment. A total of 261 eligible patients were enrolled in this study. There was no death and there were 6.51% (17/261) patients had ipsilateral stroke within 30 days. During 6 months clinical follow up, there was no death and there were 3.07% (8/261) patients had ipsilateral stroke after 30 days, and 13.41% (35/261) patients were identified with restenosis. The restenosis group had significantly higher follow-up hs-CRP (P = 0.040), higher stenosis degree (P = 0.011), higher total occlusion rate (P = 0.009), longer lesion length (P < 0.001), higher residual stenosis after intervention (P < 0.001) and lower stenting rate (P = 0.017).Multivariate logistic regression analysis showed that baseline neutrophil count (OR 1.356, 95% CI 1.015–1.812; P = 0.039), lesion length (OR 1.113, 95% CI 1.032–1.199; P = 0.005) and residual stenosis after intervention (OR 1.066, 95% CI 1.036–1.097; P < 0.001) were risk factors of restenosis.
format Article
id doaj-art-8f2a150314e646c68544648d2bdb608c
institution Kabale University
issn 2045-2322
language English
publishDate 2025-05-01
publisher Nature Portfolio
record_format Article
series Scientific Reports
spelling doaj-art-8f2a150314e646c68544648d2bdb608c2025-08-20T03:48:18ZengNature PortfolioScientific Reports2045-23222025-05-011511810.1038/s41598-025-02538-2Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic diseaseYingkun Chen0Kaiyue Dong1Yun Song2Lili Sun3Meimei Zheng4Hao Yin5Jun Zhang6Wei Wang7Yao Meng8Weili Li9Xiao He10Wei Zhao11Ju Han12Department of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalDepartment of Neurology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan HospitalAbstract Paclitaxel-coated balloon (PCB) treatment has shown promise for intracranial atherosclerotic disease (ICAD). However, studies on restenosis and its associated factors after PCB use are lacking. This study aimed to elucidate risk factors of restenosis after PCB treatment for ICAD. We retrospectively enrolled consecutive patients who had been successfully treated with PCBs for symptomatic ICAD between January 2016 and December 2022. Eligible patients were classified into “no-restenosis” and “restenosis” groups by follow-up DSA. Demographic, clinical, laboratory test, and angiographic data were analyzed. Multivariate logistic regression analysis was used to explore the risk factors of restenosis after PCB treatment. A total of 261 eligible patients were enrolled in this study. There was no death and there were 6.51% (17/261) patients had ipsilateral stroke within 30 days. During 6 months clinical follow up, there was no death and there were 3.07% (8/261) patients had ipsilateral stroke after 30 days, and 13.41% (35/261) patients were identified with restenosis. The restenosis group had significantly higher follow-up hs-CRP (P = 0.040), higher stenosis degree (P = 0.011), higher total occlusion rate (P = 0.009), longer lesion length (P < 0.001), higher residual stenosis after intervention (P < 0.001) and lower stenting rate (P = 0.017).Multivariate logistic regression analysis showed that baseline neutrophil count (OR 1.356, 95% CI 1.015–1.812; P = 0.039), lesion length (OR 1.113, 95% CI 1.032–1.199; P = 0.005) and residual stenosis after intervention (OR 1.066, 95% CI 1.036–1.097; P < 0.001) were risk factors of restenosis.https://doi.org/10.1038/s41598-025-02538-2Intracranial atherosclerotic diseasePaclitaxel-coated balloonRestenosisRisk factor
spellingShingle Yingkun Chen
Kaiyue Dong
Yun Song
Lili Sun
Meimei Zheng
Hao Yin
Jun Zhang
Wei Wang
Yao Meng
Weili Li
Xiao He
Wei Zhao
Ju Han
Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease
Scientific Reports
Intracranial atherosclerotic disease
Paclitaxel-coated balloon
Restenosis
Risk factor
title Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease
title_full Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease
title_fullStr Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease
title_full_unstemmed Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease
title_short Risk factors of restenosis after paclitaxel-coated balloon treatment in symptomatic intracranial atherosclerotic disease
title_sort risk factors of restenosis after paclitaxel coated balloon treatment in symptomatic intracranial atherosclerotic disease
topic Intracranial atherosclerotic disease
Paclitaxel-coated balloon
Restenosis
Risk factor
url https://doi.org/10.1038/s41598-025-02538-2
work_keys_str_mv AT yingkunchen riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT kaiyuedong riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT yunsong riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT lilisun riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT meimeizheng riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT haoyin riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT junzhang riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT weiwang riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT yaomeng riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT weilili riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT xiaohe riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT weizhao riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease
AT juhan riskfactorsofrestenosisafterpaclitaxelcoatedballoontreatmentinsymptomaticintracranialatheroscleroticdisease